• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-6 POS filed by Akso Health Group

    6/24/24 4:15:22 PM ET
    $AHG
    Business Services
    Consumer Discretionary
    Get the next $AHG alert in real time by email
    F-6 POS 1 e663693_f6pos-akso.htm

     

    As filed with the Securities and Exchange Commission on June 24, 2024

    Registration No. 333 - 220966

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _____________________________________

     

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-6

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933 FOR DEPOSITARY SHARES EVIDENCED BY

    AMERICAN DEPOSITARY RECEIPTS

    ______________

     

    AKSO HEALTH GROUP

    (Exact name of issuer of deposited securities as specified in its charter)

    ______________

     

    N/A

    (Translation of issuer’s name into English)

    ______________

     

    The Cayman Islands

    (Jurisdiction of incorporation or organization of issuer)

    _____________________________________

     

    CITIBANK, N.A.

    (Exact name of depositary as specified in its charter)

    ______________

     

    388 Greenwich Street

    New York, New York 10013

    (877) 248 - 4237

    (Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

    ______________

     

    Puglisi & Associates

    850 Library Avenue, Suite 204

    Newark, DE 19711

    302-738-6680

    (Address, including zip code, and telephone number, including area code, of agent for service)

    _____________________________________

     

    Copies to:

     

    Joan Wu, Esq.

    Hunter Taubman Fischer & Li LLC

    950 Third Avenue, 19th Floor

    New York, NY 10022

    212-530-2208

     

     

    Herman H. Raspé, Esq.

    Patterson Belknap Webb & Tyler LLP

    1133 Avenue of the Americas

    New York, New York 10036

    (212) 336-2301

     

    _____________________________________

     

      It is proposed that this filing become effective under Rule 466: ☒ immediately upon filing.  
        ☐ on (Date) at (Time).

     

    If a separate registration statement has been filed to register the deposited shares, check the following box: ☐

     

     

     

     

     

     

    This Post-Effective Amendment No. 2 to Registration Statement on Form F-6 may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

      

    ii

     

     

     

    PART I

     

    INFORMATION REQUIRED IN PROSPECTUS

     

    Cross Reference Sheet

     

    Item 1.DESCRIPTION OF SECURITIES TO BE REGISTERED

     

    Item Number and Caption

     

    Location in Form of American

    Depositary Receipt (“Receipt”)
    Filed Herewith as Prospectus

           
    1. Name of Depositary and address of its principal executive office   Face of Receipt -  Introductory Article.
           
    2. Title of Receipts and identity of deposited securities   Face of Receipt  - Top Center.
             
    Terms of Deposit:    
         
      (i) The amount of deposited securities represented by one American Depositary Share (“ADSs”)   Face of Receipt  - Upper right corner.
             
      (ii) The procedure for voting, if any, the deposited securities   Reverse of Receipt  - Paragraphs (17) and (18).
             
      (iii) The collection and distribution of dividends   Reverse of Receipt - Paragraph (15).
             
      (iv) The transmission of notices, reports and proxy soliciting material   Face of Receipt  - Paragraph (14);
    Reverse of Receipt – Paragraphs (17) and (18).
             
      (v) The sale or exercise of rights   Reverse of Receipt – Paragraphs (15) and (17).
             
      (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization  

    Face of Receipt – Paragraph (6);

    Reverse of Receipt - Paragraphs (15), (17), and (19).

             
      (vii) Amendment, extension or termination of the deposit agreement   Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions).
             
      (viii) Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs   Face of Receipt - Paragraph (14).

      

    I-1

     

     

     

    Item Number and Caption  

    Location in Form of American

    Depositary Receipt (“Receipt”)

    Filed Herewith as Prospectus

             

      (ix) Restrictions upon the right to deposit or withdraw the underlying securities   Face of Receipt – Paragraphs (2), (4), (6), (7), (9), and (10).
             
      (x) Limitation upon the liability of the Depositary  

    Face of Receipt – Paragraph (8);

    Reverse of Receipt - Paragraphs (20) and (21).

             
      (xi) Fees and charges which may be imposed directly or indirectly on holders of ADSs   Face of Receipt - Paragraph (11).
             
    Item 2.  AVAILABLE INFORMATION   Face of Receipt - Paragraph (14).

     

    Akso Health Group (the “Company”) is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, is required to file or submit certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission (as of the date of this Post-Effective Amendment No. 2 to Registration Statement on Form F-6) at 100 F Street, N.E., Washington D.C. 20549.

      

    I-2

     

     

     

    PROSPECTUS

     

    The Prospectus consists of the proposed form of American Depositary Receipt included as Exhibit A to the Form of Amendment No. 2 to Deposit Agreement filed as Exhibit (a)(i) to this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 and is incorporated herein by reference.

      

    I-3

     

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 3.EXHIBITS

     

    (a)(i) Form of Amendment No. 2 to the Deposit Agreement, by and among Akso Health Group (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ¾ Filed herewith as Exhibit (a)(i).

     

    (a)(ii) Amendment No. 1 to the Deposit Agreement, dated as of August 24, 2020, by and among the Company, the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ¾ Filed herewith as Exhibit (a)(ii).

     

    (a)(iii) Deposit Agreement, dated as of November 2, 2017, by and among the Company, the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (the “Deposit Agreement”). ¾ Previously filed as Exhibit (a)(ii) to the Post-Effective Amendment No. 1 to Form F-6 Registration Statement (Reg. No. 333-220966) with the Commission on August 10, 2020.

     

    (b) Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby. ¾ None.

     

    (c) Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ¾ None.

     

    (d) Opinion of counsel for the Depositary as to the legality of the securities to be registered. ¾ None.

     

    (e) Certificate under Rule 466. ¾ Filed herewith as Exhibit (e).

     

    (f) Powers of Attorney for certain officers and directors and the authorized representative of the Company. ¾ Set forth on the signature pages hereto.

      

    II-1

     

     

     

    Item 4.UNDERTAKINGS

     

    (a)The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

     

    (b)If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

      

    II-2

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, as amended, by and among Akso Health Group, Citibank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Shares issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 24th day of June, 2024.

      

     

    Legal entity created by the Deposit Agreement, as amended, under which the American Depositary Shares registered thereunder are issued, each American Depositary Share representing the right to receive the specified number of Class A ordinary shares of Akso Health Group.

     

    CITIBANK, N.A., solely in its capacity as Depositary 

         
      By:  /s/ Keith Galfo
        Name:  Keith Galfo
        Title:    Vice President

     

    II-3

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Akso Health Group certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in Qingdao, China, on June 12, 2024.

      

     

    AKSO HEALTH GROUP 

         
      By:   /s/ Yilin (Linda) Wang
        Name:  Yilin (Linda) Wang
        Title:    Chief Executive Officer

     

    II-4

     

     

     

    POWERS OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Yilin (Linda) Wang and Rui (Kerrie) Zhang to act as his/her true and lawful attorney-in-fact and agent, with full power of substitution, for him/her and in his/her name, place and stead, in any and all such capacities, to sign any and all amendments, including post-effective amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as s/he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 has been signed by the following persons in the following capacities on June 12, 2024.

     

    Signature   Title
         
    /s/ Yilin (Linda) Wang

     

    Director, Chairwoman and Chief Executive Officer (Principal Executive Officer)

    Yilin (Linda) Wang    
         
       
    /s/ Rui (Kerrie) Zhang

     

    Chief Financial Officer (Principal Financial and Accounting Officer)

    Rui (Kerrie) Zhang    
         

    /s/ Wenjuan (Vivian) Liu
     

    Director

    Wenjuan (Vivian) Liu    
         

    /s/ Stephen P. Brown
     

    Director

    Stephen P. Brown    
         

    /s/ Gerald (Jerry) T. Neal
     

    Director

    Gerald (Jerry) T. Neal    
         

    /s/ Zhe Liu
     

    Director

    Zhe Liu    

     

    II-5

     

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Akso Health Group, has signed this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 in Newark, Delaware, the U.S., on June 21, 2024.

      

    Authorized U.S. Representative:

     

    Puglisi & Associates

     
         
    By:   /s/ Donald J. Puglisi  
      Name:  Donald J. Puglisi  
      Title:    Managing Director  

     

    II-6

     

     

     

    Index to Exhibits

     

    Exhibit Document

    Sequentially

    Numbered Page 

         
    (a)(i) Form of Amendment No. 2 to Deposit Agreement  
         
    (a)(ii) Amendment No. 1 to Deposit Agreement  
         
    (e) Rule 466 Certification  

     

     

     

    Get the next $AHG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AHG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AHG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AHG Utilizes DeepSeek to Advance AI in Healthcare

      QINGDAO, China, Feb. 18, 2025 /PRNewswire/ -- Akso Health Group (NASDAQ:AHG) (hereinafter referred to as "Akso Health," "the Company," or "we") announced today its integration of DeepSeek's advanced artificial intelligence technology. This initiative aims to further enhance AI-powered medical consultation, optimize healthcare resource allocation, and provide users with more precise and efficient medical services. The utilization of DeepSeek not only represents a significant breakthrough in the field of AI-driven healthcare but also sets a new benchmark for the industry's intelligent transformation. As an innovative medical technology company, AHG leverages DeepSeek's multimodal large-scale

      2/18/25 8:30:00 AM ET
      $AHG
      Business Services
      Consumer Discretionary
    • AHG Announces Plan to Acquire Online Clinic

      QINGDAO CHINA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Akso Health Group (NASDAQ:AHG) ( "Akso Health," "the Company," or "we") today announced its plan to make an equity investment in Deyihui, an online clinic based in China. Akso Health plans to tap into the online clinic business initially in China and if the results are satisfactory, to expand this business to the other countries and regions.  Given the rapid growth of virtual consultations in mainland China, management believes this is a significant untapped market where the Company may leverage its capital resources as well as first-move advantage. The planned equity investment in Deyuhui is expected to aid management in getting famili

      1/31/24 4:00:00 PM ET
      $AHG
      Business Services
      Consumer Discretionary
    • Akso Health Group Regains Compliance with Nasdaq's Minimum Bid Price Requirement

      BEIJING, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Akso Health Group (NASDAQ:AHG) ("Akso Health" the "Company" or "we"), announced today that on October 11, 2023, it received a letter from the Nasdaq Listing Qualifications Department notifying the Company that it had regained compliance with the minimum bid price requirement. On October 26, 2022, the Company received a notification that it's American Depositary Shares ("ADS") failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Nasdaq Listing Rules of The Nasdaq Stock Market. The closing bid price of the Company's ADS was at $1.00 per share or greater from September 15, 2023 to October 10,

      10/16/23 10:30:00 AM ET
      $AHG
      Business Services
      Consumer Discretionary

    $AHG
    SEC Filings

    See more
    • Amendment: SEC Form F-3/A filed by Akso Health Group

      F-3/A - Akso Health Group (0001702318) (Filer)

      5/22/25 5:20:31 PM ET
      $AHG
      Business Services
      Consumer Discretionary
    • SEC Form 6-K filed by Akso Health Group

      6-K - Akso Health Group (0001702318) (Filer)

      5/1/25 4:35:34 PM ET
      $AHG
      Business Services
      Consumer Discretionary
    • SEC Form 6-K filed by Akso Health Group

      6-K - Akso Health Group (0001702318) (Filer)

      3/28/25 4:05:19 PM ET
      $AHG
      Business Services
      Consumer Discretionary